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santé et de la recherche médicale, Toulouse, France, 7 French National Agency for Medicines and Health Products Safety, Saint Denis, France, 8Medical Doctor -
Consultant, Paris, France, 9Department of Vaccinology, Swedish Institute for Infectious Disease Control, Solna, Sweden, 10Department Medical Epidemiology and
Biostatistics, Karolinska Institute, Stockholm, Sweden, 11National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 12Departments of
Neurology and Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands, 13Department of Vaccination and Immune Protection, National Institute
for Health and Welfare, Helsinki, Finland, 14Department of Vaccines, Norwegian Institute of Public Health, Oslo, Norway, 15 Surveillance and Response Support Unit,
European Centre for Disease Prevention and Control, ECDC, Stockholm, Sweden, 16 Brighton Collaboration Foundation, Basel, Switzerland, 17Department of Infectious
Diseases and Vaccinology, University Children’s Hospital, Basel, Switzerland
Abstract
Background: The risk of Guillain-Barré syndrome (GBS) following the United States’ 1976 swine flu vaccination campaign in
the USA led to enhanced active surveillance during the pandemic influenza (A(H1N1)pdm09) immunization campaign. This
study aimed to estimate the risk of GBS following influenza A(H1N1)pdm09 vaccination.
Methods: A self-controlled case series (SCCS) analysis was performed in Denmark, Finland, France, Netherlands, Norway,
Sweden, and the United Kingdom. Information was collected according to a common protocol and standardised
procedures. Cases classified at levels 1–4a of the Brighton Collaboration case definition were included. The risk window was
42 days starting the day after vaccination. Conditional Poisson regression and pooled random effects models estimated
adjusted relative incidences (RI). Pseudo likelihood and vaccinated-only methods addressed the potential contraindication
for vaccination following GBS.
Results: Three hundred and three (303) GBS and Miller Fisher syndrome cases were included. Ninety-nine (99) were exposed
to A(H1N1)pdm09 vaccination, which was most frequently adjuvanted (Pandemrix and Focetria). The unadjusted pooled RI
for A(H1N1)pdm09 vaccination and GBS was 3.5 (95% Confidence Interval (CI): 2.2–5.5), based on all countries. This lowered
to 2.0 (95% CI: 1.2–3.1) after adjustment for calendartime and to 1.9 (95% CI: 1.1–3.2) when we accounted for contra-
indications. In a subset (Netherlands, Norway, and United Kingdom) we further adjusted for other confounders and there
the RI decreased from 1.7 (adjusted for calendar month) to 1.4 (95% CI: 0.7–2.8), which is the main finding.
Conclusion: This study illustrates the potential of conducting European collaborative vaccine safety studies. The main, fully
adjusted analysis, showed that the RI of GBS was not significantly elevated after influenza A(H1N1)pdm09 vaccination
(RI = 1.4 (95% CI: 0.7–2.8). Based on the upper limits of the pooled estimate we can rule out with 95% certainty that the
number of excess GBS cases after influenza A(H1N1)pdm09 vaccination would be more than 3 per million vaccinated.
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Introduction
During the influenza A (H1N1) 2009 pandemic, new monova-
lent adjuvanted and non-adjuvanted influenza A(H1N1)pdm09
vaccines were introduced in Europe. Immunogenicity and safety
was in line with the ‘‘Committee for medicinal products for human
use (CHMP) Note for Guidance’’, but safety data were limited [1–
3]. Vaccination campaigns started in autumn 2009 at the peak of
the pandemic in Europe.
A key safety concern identified in planning the pandemic
vaccination campaigns was the potential association between
Guillain-Barré syndrome (GBS) and influenza vaccines; this
concern stemmed from an association observed in the USA in
1976 between swine flu vaccination and GBS [4]. Subsequent
prospective surveillance studies and retrospective epidemiological
studies on seasonal influenza vaccines used in 1978, 1992, 1993,
and beyond showed no or modest increases in the risk of GBS [5–
8]. Despite this, the US Food and Drug Administration (FDA), the
World Health Organization (WHO) and the European Medicines
Agency (EMA) recommended active monitoring of a potential
association between the influenza A(H1N1)pdm09 vaccine and
GBS.
In Europe, GBS primarily presents as an acute inflammatory
demyelinating polyradiculoneuropathy (AIDP) [9]. Three to ten
per cent of GBS patients die and an estimated 20% experience
continued disability for more than six months [10]. Prospective
studies in developed countries have estimated an incidence rate of
2 per 100,000 population per year with an increased risk with age
and in males [11]. GBS is thought to be primarily triggered by a
preceding respiratory or gastrointestinal infection [12].
The European Centre for Disease prevention and Control
(ECDC) commissioned the VAESCO (Vaccine Adverse Events
Surveillance and Communication) consortium to study the
potential association between influenza A(H1N1)pdm09 vaccine
and GBS. A case control study was conducted for a rapid initial
assessment with a large-scale more extensive prospective SCCS
study carried out in parallel. The VAESCO case control study was
based on 104 cases in five European countries and showed no
association between A(H1N1)pdm09 vaccine (mostly adjuvanted
with AS03) and GBS [13]. In this paper we present the results




The VAESCO consortium conducted a prospective self-
controlled case series (SCCS) study to investigate the association
between influenza A(H1N1)pdm09 vaccination and GBS. A
SCCS is a case-only study comparing the incidence of disease
during risk and non-risk periods within the same person,
inherently controlling for measured and unmeasured confounding
factors that remain stable over time [14].
The VAESCO consortium was initiated and core funded by
ECDC with the aim of improving post licensure vaccine safety in
Europe. It is coordinated by the Brighton Collaboration Founda-
tion and includes partners from public health organizations,
regulatory authorities and academic research institutions in
Europe.
Centers from Denmark (DK), Finland (FI), France (FR),
Netherlands (NL), Norway (NO), Sweden (SE), and the United
Kingdom (UK) contributed to the study. All centers used a
common protocol and applied the standardised Brighton Collab-
oration GBS case definition for case classification [9]. Implemen-
tation of the protocol and data collection differed per country
based on ethical requirements and the healthcare structure. Data
harmonization, transformation, and pooling used methods and
tools derived from the EU-ADR (Exploring and Understanding
Adverse Drug Reactions) project [15]. Centers created harmo-
nized input files according to well-defined instructions. These data
files were generated directly from automated resources or
manually using customized electronic case report forms. The
harmonized input files were transformed using a standardized
JAVA-based program (JerboaH version 2.6.0, September 2010,
Erasmus University Medical Center, Rotterdam, Netherlands).
Only anonymous and aggregated de-identified information
without dates of disease or exposure were shared for individual
patient level data pooling and centralised analysis. Consent forms,
original data and Jerboa input files were retained at the local
centers. Quality control and verification of transmitted data was
done at the central data management and analysis center (Erasmus
University) in close collaboration with the other centers. All
centers commented on the data and results prior to release.
Source and study population
The total source population exceeded 50 million (M) subjects,
with most countries recruiting cases on a national level (NO (4.4
M), SE (9 M), FI (5.5 M), DK (5 M), NL (16 M)). In the UK, the
General Practice Research Database (GPRD) (5 M) was used and
in France specialized hospitals with a large but undefined
catchment area participated. Case recruitment started on 1st
November 2009 and lasted maximally until 1st November 2010.
The study population encompassed all cases with GBS or its
variant Miller Fisher syndrome with onset of disease during the
study period.
Case recruitment-procedures are described in Table 1. Com-
pleteness of recruitment was verified retrospectively at the end of
the study period by comparing recruited cases with diagnosed case
lists (see Table 1). Additional cases identified in this way were
Guillain-Barré Syndrome and A(H1N1) Vaccines in EU
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included retrospectively where possible. For each subject, follow-
up started at the beginning of the study period or date of birth if
born after the start of the study period. Follow-up ended with the
end of the study period or death occurring prior to the end of the
study period.
The earliest date of onset of neurological symptoms was the
index date. If the date of first symptoms could not be retrieved the
date of diagnosis or hospitalization was used. Informed consent
was required in SE and FR. Case characteristics were obtained
from neurologists or from discharge letters and used to classify
cases according to the Brighton Collaboration GBS Case
Classification using the Automated Brighton Classification (ABC)
tool (www.brightoncollaboration.org).
Vaccine Exposure
The primary exposure of interest was vaccination with
adjuvanted or non-adjuvanted A(H1N1)pdm09 vaccine as record-
ed in vaccination registries (FR, DK, FI, NO), General Practi-
tioners’ (GP) records (NL, UK), or patient interview (SE). The risk
period began the day after vaccination and ended 42 days later. If
two doses were administered, the risk period of the first dose ended
when the second dose was administered. Brand specific informa-
tion was collected for each influenza A(H1N1)pdm09 vaccination.
Covariates
Information on several time varying risk factors for GBS was
collected during follow-up including seasonal influenza vaccina-
tion, influenza-like illness (ILI), upper respiratory tract infections
(URTI), and gastrointestinal infections (GI). Each of these
covariates was assigned a 42-day risk period. The risk period
began on day one of onset of ILI, URTI, or GI or of seasonal
influenza vaccine receipt and ended 42 days after onset or
exposure. Covariate data were not collected in DK and FI. In FR,
covariate data were collected from neurologists at case occurrence
for the period prior to GBS only, whereas in SE data on covariates
were collected by interview at the end of follow-up. In the UK,
NL, and NO general practitioner records were used to collect
information on covariates throughout the follow up period; NO
also assessed covariates reported by neurologists at the time of case
data collection, leading to a potential for differential data
collection over time. To adjust for seasonal effects, changes in
circulation of the wild type influenza A(H1N1)pdm09 virus and
Table 1. Sources of cases, exposure and covariate information per country.
Cases recruitment Exposure Information
Covariates during
follow-up Potential bias
DK Cases were identified from the National Patient Register
using primary discharge diagnoses only (ICD-10: G61.0).
Case validation based on retrospective chart review.
Vaccination registry None (only from
case hospital charts)
Cases: not all charts available
No ability to control for time
varying confounders
FI From hospital Discharge and hospital outpatient records,
primary diagnoses (ICD-10 G61.0). Case validation based
on retrospective chart review
Vaccination registry None (only from
case hospital charts)
Cases: not all charts available
No ability to control for time
varying confounders
FR Cases were identified prospectively through neurologists
in 7 reference hospitals in FR. Patients needed to provide
informed consent. Completeness was verified against
pharmacy data (immunoglobulin prescriptions) and
showed incomplete reporting (,50%), Vaccination status
of non-reported cases could not be verified since linkage





period prior to GBS
Incompleteness and potential
selection bias cannot be
excluded.
No ability to control for time
varying confounders
NL Cases were identified prospectively through neurologists.
Completeness was verified retrospectively by checking
against the claims codes in each of the reporting hospitals.
Missing patients were included retrospectively in hospitals
that were reporting at least one case prospectively.
GP medical record GP medical record Small potential for
misclassification of exposure
since A(H1N1)pdm09 vaccination
could also be provided through
public health agency for parents
of young children
NO Nationwide neurologist reporting network, group of
neurologists. Case validation based on review of GBS
experts
Vaccination registry Neurologists, Hospitals,
and GPs
Potential selection due to
incompleteness
Information on co-variates
collected differently for period
prior to GBS.
SE Cases of GBS were identified through seven neurology
assessment labs where GBS cases are laboratory confirmed
for a population of 9.4 million. Informed consent needed to
be obtained from all cases. Completeness of cases was
checked in the National Patient Registry for part of the country.
Recruitment was incomplete because of delays in consent and
non-consent. It was not possible to assess whether this
non-response differed by vaccination status and hence
selection bias cannot be excluded.
By interview at end of
follow-up, recall bias cannot
be excluded.
By interview for cases
at the end of follow up.
change in region over




Recall bias (differential recall over
time)
UK Each case was identified in the General Practice Research
Database by using appropriate READ codes (F370.00,
F370000, F370100, F370200, F370z00). Case verification
was done using any hospital letters, discharge summaries
and GPs’ notes recorded as free text. No major selection
to be expected
Automated GP records, no
recall bias. Non-differential
misclassification possible
since some persons might
have been vaccinated
outside of GP office.
GP records Misclassification of cases due to
lack of information on test results
doi:10.1371/journal.pone.0082222.t001
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differences in case inclusion over the observation period we
considered calendar month as a time varying covariate.
Statistical Analysis
The RI for the association between A(H1N1)pdm09 vaccine
and GBS was estimated using a conditional Poisson regression
analysis. This was done for each country separately. Adjustment
for calendar month was possible in all countries, whereas further
adjustment for ILI, URTI, GI, and seasonal influenza vaccination
was only possible in NL, UK, and NO. Sensitivity analyses were
used to assess the effects of misclassification of exposure and
confounding. An analysis using vaccinated cases only and an
analysis using the pseudo-likelihood approach explored confound-
ing by contra-indication to influenza A(H1N1)pdm09 vaccination
[14]. A sub analysis was done to assess the impact of residual
confounding by ILI, URTI, seasonal influenza vaccination, and
GI infections. Misclassification of the risk period was investigated
by applying risk periods smaller than 42 days. In order to study
effect modification by infections occurring just prior to GBS onset,
stratified analyses were carried out for age, sex, history of GBS,
Figure 1. Flowchart of case inclusion.
doi:10.1371/journal.pone.0082222.g001
Figure 2. Inclusion of GBS cases (DK, FI, FR, NL, NO, SE, UK), influenza A(H1N1)pdm09 immunization period (influenza A(H1N1)vac),
and percentage of flu positive cases among all tested per country (Flu pos. DK, …, Flu pos. UK; Source: ECDC 2011) over total study
period.
doi:10.1371/journal.pone.0082222.g002
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and prior infections (ILI, URTI, GI) in UK, NL, and NO. The
country specific estimates were pooled applying a random effects
model. All analysis used SAS v9.1 (Cary, North Carolina).
Results
In total 730 potential GBS cases were identified during the
study period. Of these, 427 cases were excluded (see figure 1),
leaving 303 GBS cases in the study population. Case inclusion
declined over time from 133 cases in the first three months to 18 in
the last three months (Figure 2). The percentage of influenza A
(H1N1) pdm09 vaccinated cases did not change significantly over
time (R2= 0.094; Figure 3).
Cases had a mean age of 50 years (SD: 4.1) ranging from 45
(SD: 20.8) years in the NL to 56 (SD: 19.5) years in NO, less than
10% were younger than 20 years. On average the follow-up period
was 321 days. Case classification differed by country, primarily
depending on the type of data source used for case recruitment. Of
all cases, 36% were classified as Brighton Collaboration level 1,
26% as level 2, 13% as level 3, and 25% as level 4a. In 69 cases
electrophysiology (mostly AIDP) had either not been performed
for diagnosis or was not recorded. On a scale from 0 to 6, with 0
meaning complete physical fitness and 6 meaning death, the
disability score was most frequently 4 (30.6%) (Table 2).
Overall, 99 cases (33%) received influenza A(H1N1)pdm09
vaccination, mostly adjuvanted with AS03, before symptom onset
(Table 3). Of these, 36 (37%) cases developed GBS within 42 days
after a first dose of influenza A(H1N1)pdm09 vaccination whereas
7 cases occurred within the exposure risk window but after a
second dose of influenza A(H1N1)pdm09 vaccination.
Few countries could collect data on time-varying covariates over
the entire follow-up period. Most countries assessed covariates at
the time of case collection, but not afterwards, and therefore these
data could not be utilized for adjustments but could be used for
stratification. Based on the information collected at case occur-
rence, 15 cases developed GBS within 42 days after seasonal
influenza vaccination and 79 cases developed GBS within 42 days
after onset of ILI or URTI (Table 3).
Risk ratio of GBS
The crude country specific RI of GBS during the influenza
A(H1N1)pdm09 vaccination risk period compared to the non-risk
period varied from a low of 1.6 in FI to a high of 7.7 in DK (based
on two exposed cases only), with an overall pooled estimate of 3.5
(95% CI: 2.2 to 5.5). Adjustment for calendar month had a
significant impact (RI: 2.0, 95% CI: 1.2 to 3.1). Sensitivity analyses
accounting for contra-indication after GBS onset showed a minor
change in the calendar month adjusted pooled RI from 2.0 to 1.9
(95% CI: 1.1 to 3.2) when the pseudolikelihood method was used,
and 1.8 (95% CI: 0.7 to 4.7) when considering vaccinated cases
only (Table 4).
In NL, NO, and the UK where further adjustment for
infections, seasonal influenza vaccination, and other time depen-
dent covariates was possible, the RI for the association between
influenza A(H1N1)pdm09 vaccination and GBS decreased from
the unadjusted pooled RI of 3.2 (95% CI: 1.8 to 5.6) to 1.7 (95%
CI: 0.8 to 3.4) after adjustment for calendar month, and to 1.4
(95% CI: 0.7 to 2.8) upon further adjustment for ILI, URTI, and
GI.
Sensitivity analyses using different post-exposure risk periods
resulted in a calendar month-adjusted pooled RI of 2.3 (95% CI:
1.4 to 3.8) for the first four weeks. The RI was 2.3 (95% CI: 1.2 to
4.4) in the first two weeks and 2.6 (95% CI 1.4 to 4.9) during weeks
three to four.
We did not observe statistically significant interactions between
age, infections, or seasonal influenza vaccination and the
association between the influenza A(H1N1)pdm09 vaccination
and GBS (Table 5).
Discussion
Based on a source population of more than 25 million subjects
from NL, UK, and NO we found no significant elevated
association between the risk of GBS following immunization with
an adjuvanted influenza A(H1N1)pdm09 vaccine, when adjusted
for all known measurable confounders (RI 1.4, 95% CI: 0.7 to
2.8). This result is very similar to that of the VAESCO consortium
case control study, published previously using one third of the
cases from fewer countries [13]. In DK, FI, FR and SE we could
not adjust for time varying confounders such as infections since
data were not collected over the entire follow up period. Pooling
data from all seven countries yielded a crude RI of 3.5, which
reduced to 2.0 (95% CI: 1.2 to 3.1) after adjustment for calendar
month: this pooled estimate still comprises residual confounding
by infections. The effect of calendar month may be explained by it
being a good proxy for circulation of the wild-type influenza
A(H1N1)pdm09 virus (see figure 2).
Figure 3. Inclusion of vaccinated cases (% of population) over study period.
doi:10.1371/journal.pone.0082222.g003
Guillain-Barré Syndrome and A(H1N1) Vaccines in EU
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e82222
Table 2. Characteristics of Guillain-Barré syndrome cases.
Characteristic DK FI FR NL NO SE UK Total
N % N % N % N % N % N % N % n %
Cases in study period 31 10.2 29 9.6 41 13.5 80 26.4 50 16.5 32 10.6 40 13.2 303 100
Females 14 45.2 12 41.4 20 48.8 32 40.0 25 50.0 12 37.5 17 42.5 132 43.6
Mean age (SD)1 [years] 49.2 (20.2) 54.4 (20.8) 50.0 (21.9) 45.0 (20.8) 55.5 (19.5) 51.5 (20.2) 45.4 (20.4) 50.1 (4.1)
Age #4 0 0.0 0 0.0 1 2.4 2 2.5 1 2.0 0 0.0 2 5.0 6 2.0
Age 5–19 years 3 9.7 3 10.3 4 9.8 10 12.5 0 0.0 2 6.3 3 7.5 25 8.3
Age 20–59 years 18 58.1 10 34.5 18 43.9 44 55.0 21 42.0 15 46.9 24 60.0 15 49.5
Age $60 10 32.3 16 55.2 18 43.9 24 30.0 28 56.0 15 46.9 11 27.5 122 40.3
Brighton Classification2
1 10 32.3 17 58.6 13 31.7 28 35.0 21 42.0 19 59.4 0 0.0 108 35.6
2 8 25.8 3 10.3 16 39.0 30 37.5 14 28.0 8 25.0 0 0.0 79 26.1
3 4 12.9 7 24.1 7 17.1 11 13.8 5 10.0 5 15.6 0 0.0 39 12.9
4a 9 29.0 2 6.9 5 12.2 10 12.5 10 20.0 0 0.0 40 100.0 76 25.1
Unknown 0 0.0 0 0.0 0 0.0 1 1.3 0 0.0 0 0.0 0 0.0 1 0.3
Electrophysiology
AIDP3 23 74.2 16 55.2 15 36.6 36 45.0 29 58.0 23 71.9 0 0.0 142 46.9
AMAN4 0 0.0 0 0.0 1 2.4 6 7.5 3 6.0 0 0.0 0 0.0 10 3.3
AMSAN5 1 3.2 2 6.9 0 0.0 4 5.0 1 2.0 6 18.8 2 5.0 16 5.3
Equivocal 0 0.0 0 0.0 6 14.6 9 11.3 7 14.0 1 3.1 0 0.0 23 7.6
Normal 2 6.5 0 0.0 2 4.9 3 3.8 6 12.0 0 0.0 0 0.0 13 4.3
Not performed 5 16.1 11 37.9 12 29.3 20 25.0 3 6.0 2 6.3 0 0.0 53 17.5
Unresponsive nerves 0 0.0 0 0.0 0 0.0 1 1.3 1 2.0 0 0.0 0 0.0 2 0.7
Unknown 0 0.0 0 0.0 5 12.2 1 1.3 0 0.0 0 0.0 38 95.0 44 14.5
GBS disability score6
0 0 0 0 0.0 6 14.6 0 0.0 0 0.0 0 0.0 0 0 6 2.0
1 0 0 0 0.0 0 0.0 5 6.3 7 14.0 1 3.1 0 0 13 4.3
2 0 0 9 31.0 2 4.9 19 23.8 11 22.0 6 18.6 0 0 47 15.5
3 0 0 4 13.8 10 24.4 21 26.3 6 12.0 7 21.9 0 0 48 15.8
4 0 0 13 44.8 11 26.8 20 25.0 17 34.0 10 31.3 0 0 71 23.4
5 0 0 2 6.9 2 4.9 13 16.3 8 16.0 7 21.9 0 0 32 10.6
6 0 0 1 3.4 0 0.0 1 1.3 1 2.0 1 3.1 0 0 4 1.3
Unknown 31 100.0 0 0.0 10 24.4 1 1.3 0 0.0 0 0.0 40 100.0 82 27.1
Index month
Nov 2009 9 29.0 4 13.8 9 22.0 5 6.3 5 10.0 8 25.0 6 15.0 46 15.2
Dec 2009 1 3.2 5 17.2 8 19.5 22 27.5 12 24.0 6 18.8 4 10.0 58 19.1
Jan 2010 6 19.4 5 17.2 9 22.0 8 10.0 8 16.0 3 9.4 5 12.5 44 14.5
Feb 2010 5 16.1 6 20.7 6 14.6 9 11.3 1 2.0 5 15.6 8 20.0 40 13.2
Mar 2010 4 12.9 3 10.3 3 7.3 5 6.3 4 8.0 3 9.4 6 15.0 28 9.2
Apr 2010 3 9.7 5 17.2 4 9.8 7 8.8 4 8.0 2 6.3 3 7.5 28 9.2
May 2010 3 9.7 1 3.4 1 2.4 8 10.0 3 6.0 2 6.3 1 2.5 19 6.3
Jun 2010 0 0.0 0 0.0 1 2.4 2 2.5 3 6.0 3 9.4 3 7.5 12 4.0
Jul 2010 0 0.0 0 0.0 0 0.0 3 3.8 3 6.0 0 0.0 1 2.5 7 2.3
Aug 2010 0 0.0 0 0.0 0 0.0 4 5.0 2 4.0 0 0.0 2 5.0 8 2.6
Sep 2010 0 0.0 0 0.0 0 0.0 4 5.0 4 8.0 0 0.0 0 0.0 8 2.6
Oct 2010 0 0.0 0 0.0 0 0.0 3 3.8 1 2.0 0 0.0 1 2.5 5 1.7
TOTAL 31 29 41 80 50 32 40 303
1Standard Deviation.
2Sejvar J. J. et al. 2011, Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety
data. Vaccine 29(3).
3AIDP: acute inflammatory demyelinating polyradiculoneuropathy.
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This study is unique as it directly pools data on individual
patients from seven European countries, using a common
protocol, common case definition, common infrastructure, and
common data elaboration. The impact of methodological issues
that occurred due to differences in implementation of the protocol
could be assessed by comparing the association accross countries;
the consistency observed is reassuring. Beyond the effect of the
influenza A(H1N1)pdm09 vaccination on GBS this study under-
lines the advantages of collaborative transnational vaccine safety
studies. They not only increase the scale of a study, but also allow
for consistency- checks across sources in the absence of bias from
differences in design and methods. The use of common methods
and subsequent pooling reaches far beyond the traditional
approach of meta-analyses where rather heterogeneous estimates
resulting from different designs, methods, and settings are being
pooled.
The data from this VAESCO study are in line with other results
from Europe with studies from FR (RI 0.9, 95% CI: 0.1 to 7.6)
[16], SE (RI 1.1 95% CI: 0.6 to 1.9) [17], and the UK (RI 1.05,
95% CI: 0.37–2.24) [18], all showing no association. In contrast, a
recent report from Germany, where AS03 adjuvanted vaccine was
used, showed an increased risk of GBS after vaccination (RI 4.65,
95% CI: 2.17 to 9.98) [19]. German investigators had already
started a separate SCCS study and thus elected not to participate
in VAESCO. They did not adjust for infections or calendar-time
and selection bias could not be excluded since cases originated
from a reporting network. Pooling of calendarmonth adjusted RI
estimates with the VAESCO study would be possible through
meta-analysis to enlarge the scale of the current EU based study.
Five studies from the US, where non-adjuvanted influenza
A(H1N1)pdm09 vaccines were used, have recently been published.
Each of the initial observational studies found an increased RI
ranging from 1.6 (95% CI: 1.0 to 2.2) [20], to 2.1 (95% CI: 1.2 to
3.5) [21], to 2.5 (95% CI: 0.42 to 15.0) [22], and to 4.4 (95% CI:
1.3 to 14.2) [23]. Three studies used self-controlled designs but
without further adjusting for time-varying confounders [21–23].
The study assessing the lowest RI (1.6 (95% CI: 1.0 to 2.2)) was a
cohort study adjusting for age and sex [20]. The highest RI of 4.4
(95% CI: 1.3 to 14.2) was based on data from the US Vaccine
Safety Datalink (VSD) project, which was based on 13 vaccinated
cases [23]. Salmon et al. recently published a meta-analysis of US
studies on the association between influenza A(H1N1)pdm09
vaccines including two unpublished studies and reported a pooled
estimate of 2.35 (95%CI: 1.42–4.01) [24]. A SCCS study from
Quebec, Canada adjusted for seasonality and contraindication
using vaccinated cases only reported a relative risk of 1.9 (95% CI:
1.0 to 3.5) [25]. After the first VSD study, a second VSD study was
recently published, investigating specifically the effect of anteced-
ent infections on the relative incidence of GBS following influenza
A(H1N1)pdm09 vaccines, using a case centered analysis. This
analysis showed the impact of infections as a confounding factor
[26]. After adjusting for antecedent infections, there was no
evidence for an elevated GBS risk following 2009–10 monovalent/
2010–11 trivalent influenza vaccines. However, the association
between GBS and antecedent infection was strongly elevated. The
effect of infections on the risk of GBS and the potential preventive
effect of vaccination on the risk of GBS by preventing influenza
was recently discussed by Stowe and Poland [27,28]. This recent
evidence underlines the need to adjust for infections as we could
do in part of the countries in our analyses.
Owing to its observational nature, our study suffers from
limitations that should be considered when interpreting data. In
NL and SE, where reporting networks were used, completeness of
recruitment was verified by retrospectively comparing included
cases with claims made for GBS. In FR and SE informed consent
was required which could be another reason for non-inclusion.
Finally, since cases were included only if charts/medical records
could be reviewed, lack of data could be another source of
selection bias. The distribution of vaccinated cases over time
showed no significant trend, suggesting changes in the number of
cases included over time were not related to exposure and
selection bias may be limited (Figure 3).
Information bias may arise from misclassification of the
outcome as well as the exposure. Cases recruited directly from
neurologists (i.e., FR, NL, NO, and SE) generally had higher levels
of diagnostic certainty. In the UK all cases were classified with the
lowest Brighton Collaboration case certainty level as information
was retrieved retrospectively from GP medical records, which
capture information from specialist letters but often lack informa-
tion on specific test results. In DK cases were classified based on
retrospective review of specialist charts resulting in partially
missing information. As standardized criteria were used for case
classification, misclassification of the outcome will be minimal. In
all countries prospectively collected health care records were used
to obtain information on exposure, except in SE, which relied on
interviews and may have suffered from recall bias. In the NL
exposure may have been misclassified in young children (,5 years)
who were participating in mass vaccination campaigns, but this
will be non-differential and there were very few paediatric cases.
Exposure might be misclassified due to misspecification of the risk
period. Sensitivity analysis showed no difference in the RI when
the risk window was restricted to 15 to 28 days after vaccination
(RI 2.6, 95% CI: 1.4 to 4.9); compared to the first two weeks (RI
2.3, 95% CI 1.2 to 4.4) and the risk in a 4-week risk window (RI
2.3, 95% CI 1.4 to 3.8).
We addressed confounding both by design (SCCS controls for
time-constant confounders), through adjustments, and sensitivity
analyses. GBS could be a contra-indication for influenza
A(H1N1)pdm09 vaccine as a similar vaccine had been associated
with GBS in the past. To investigate this issue we carried out
analyses including only vaccinated subjects and analyses applying
the pseudo-likelihood method [14]. The pseudo-likelihood method
reduced the calendar-adjusted pooled RI from 2.0 to 1.9 and if
only vaccinated cases were included to 1.8, indicating that contra-
indications were a minor issue. Calendar month acted as an
important confounding factor, not because time itself is a risk
factor, but because it may serve as a proxy for influenza
A(H1N1)pdm09 circulation, which was highly time-dependent
and co-occuring with the mass vaccination campaigns (see
figure 2). Adjustment for additional timevarying confounders
4AMAN: acute motor axonal neuropathy.
5AMSAN: acute motor and sensory axonal neuropathy.
6Current disability score at the time of case assessment and/or inclusion into the study.
Abbreviations: DK: Denmark; FI: Finland; FR: France; NL: Netherlands; NO: Norway; SE: Sweden; UK: United Kingdom; GBS: Guillain-Barré syndrome.
doi:10.1371/journal.pone.0082222.t002
Table 2. Cont.
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(mainly infections) lowered the pooled calendar-month adjusted
RI in NL, NO, and UK from 1.7 to 1.4. This is in line with the
effect of control for infections seen by Greene et al [26]. The effect
of infections on the risk of GBS differed substantially between
countries due to differences in timing and type of data collection
methods. In future studies, standardization of covariate exposure
Table 4. Relative incidence estimates for the association between infections, influenza A(H1N1)pdm09 vaccination, seasonal
influenza vaccination and Guillain-Barré syndrome.
DK FI FR NL NO SE UK Pooled
RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI
Covariates
ILI NA NA NA 10.5 3.0–36.3 30.6 8.6–108 NA 1.8 0.2–16.0 10.4 2.6–41.1
URTI NA NA NA 13.0 4.3–39.2 17.7 6.2–34.7 NA 2.2 0.4–10.6 8.51 3.0–24.0
GI NA NA NA 11.6 2.8–49.4 53.31 6.56–433 NA 2.3 0.2–22.6 11.9 2.5–55.6
Seasonal influenza vaccination NA NA NA 1.2 0.4–4.0 5.5 1.6–18.9 NA 6.0 1.8–19.7 3.9 1.8–8.3
Any influenza A(H1N1)pdm09 vaccination
Unadjusted 7.7 1.1–54.4 1.6 0.5–5.4 6.4 1.0–40.4 2.7 1.3–5.9 3.9 1.6–9.3 4.8 2.1–11.1 3.3 0.3–36.5 3.5 2.2–5.5
Adjusted for calendar month 3.9 0.5–32.2 1.6 0.5–5.4 2.9 0.4–19.6 1.4 0.6–3.4 1.9 0.7–5.2 2.7 1.0–7.8 2.3 0.2–27.7 2.0 1.2–3.1
Adjustment effect any influenza A(H1N1)pdm09 vaccination in NL, NO, UK
Adjusted for calendar month
only
1.4 0.6–3.4 1.9 0.7–5.2 2.3 0.2–27.7 1.7 0.8–3.4
Fully adjusted (month, ILI/URTI,
GI)
1.2 0.5–3.3 1.5 0.5–4.6 1.5 0.1–23.1 1.4 0.7–2.8
Sensitivity analysis on influenza A(H1N1)pdm09 vaccination for contra-indication
Pseudolikelihood
1st dose 3.6 0.4–29.5 3.2 0.7–14.6 0.6 0.1–6.7 1.3 0.4–4.0 1.6 0.6–4.3 2.4 0.8–6.9 4.8 0.3–83.9 1.9 1.1–3.2
2nd dose NA NA 2.2 0.2–26.3 1.2 0.4–3.4 NA NA NA 1.3 0.5–3.4
Vaccinated cases only NE 2.6 0.2–32.5 NE 1.2 0.2–8.3 1.6 0.3–7.9 2.5 0.4–16.0 NE 1.8 0.7–4.7
Abbreviations: NA: not available or not valid; NE =Not estimable due to small numbers or absence RI: relative incidence; ILI: influenza like illness; URTI: upper respiratory
tract infection, GI: gastrointestinal Infection, UK: United Kingdom; NL: Netherlands; FR: France; SE: Sweden; FI: Finland, NO: Norway, DK: Denmark.
doi:10.1371/journal.pone.0082222.t004
Table 5. Stratified analyses for association between influenza A(H1N1)pdm09 vaccination and Guillain-Barré Syndrome.




RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI RI 95% CI
Changing risk windows
1–28 days 4.4 (0.5 to 35.6) 1.0 (0.2–4.6) 1.3 (0.1–12.6) 2.5 (1.0–6.4) 2.2 (0.8–6.1) 2.7 (0.9–7.8) 4.2 (0.4–50.2) 2.34) (1.4–3.8)
1–14 days 7.6 (0.9–61.7) 2.3 (0.5–10.6) 3.4 (0.3–33.3) 2.5 (0.7–9.3) 1.3 (0.3–5.9) 1.0 (0.2–4.7) 10.8 (0.9–133.2) 2.35) (1.2–4.4)
15–28 days NE3) 0.0 0.0 1.9 (0.7–5.5) 2.5 (0.8–7.8) 3.7 (1.2–11.1) 2.6 (1.4–4.9)
42 day risk window
19–59 years old 0.0 3.3 (0.5–19.3) 1.0 (0.1–10.7) 0.6 (0.1–5.5) 1.0 (0.2–6.6) 1.3 (0.5–3.6)
older than 59 years 2.3 (0.1–38.0) 0.0 0.0 1.1 (0.3–4.9) 3.5 (1.0–12.6) 7.6 (1.6–35.8) 11.9 (0.4–365.5) 3.2 (1.5–6.9)
Co-morbidities1) 0.0 2.5 (0.2–35.5) 0.24 0.0 3.2 (0.6–17.0) 0.0 3.0 (0.7–12.3)
No co-morbidities1) 0.0 1.7 (0.4–6.7) 1.7 (0.1–19.6) 1.9 (0.6–6.6) 1.4 (0.4–5.3) 0.0 1.7 (0.8–3.4)
Seasonal influenza
vacvination
0.0 3.0 (0.2–50.4) 0.2 0.5 (0.1–3.6) 2.1 (0.2–19.0) 0.0 1.2 (0.3–4.5)
No seasonal influenza
vaccination
0.0 1.6 (0.4–6.4) 4.8 (0.3–83.6) 2.2 (0.4–11.2) 1.7 (0.6–5.4) 0.0 1.9 (0.9–4)
ILI, URTI infection NE 1.1 (0.1–10.6) 2.9 (0.2–51.9) 1.1 (0.1–11.4) 1.4 (0.4–4.8) 3.2 (0.8–14.0) 1.8 (0.8–3.9)
No ILI, URTI infection 2.5 (0.2–34.4) 2.2 (0.5–10.3) 0.0 1.5 (0.4–5.8) 3.6 (0.5–24.3) 2.7 (0.6–13.2) 2.2 (1.1–4.7)
1)Malignancy, immune suppression, or autoimmune disorder NE =Not estimable due-small numbers.
Abbreviations: RI, relative incidence; ILI, influenza like illness; URTI, Upper respiratory tract infection; UK, United Kingdom; NL, Netherlands; FR, France; SE, Sweden; FI,
Finland, NO, Norway, DK, Denmark.
doi:10.1371/journal.pone.0082222.t005
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reporting will have to be addressed in more detail. Given the
variation in the RI of GBS among other countries’ A(H1N1)pdm09
vaccinees, these results, as well as the pooled estimate that was
adjusted for calendar month only, are likely affected by residual
confounding by infections.
Conclusion
This large, multinational SCCS study confirms the results from
the initial much smaller VAESCO case control study. In each
country, the unadjusted association between influenza
A(H1N1)pdm09 vaccine and GBS suggests a possible increase in
risk, and adjustment for confounders consistenly lowered this risk.
Further adjustment for infections could only be carried out in some
countries and demonstrated the effect of confounding by ILI, GI
and URTI, which themselves were strong risk factors for GBS. After
adjustment we did not observe an association between influenza
A(H1N1)pdm09 vaccine and GBS. Based on the upper limit of the
confidence interval of both the partially and fully adjusted RI
estimates we can rule out with 95% certainty that adjuvanted
influenza A(H1N1)pdm09 vaccines (mainly AS03 adjuvanted)
would have resulted in more than 2 or 3 excess cases of GBS per
1 million vaccinated persons.
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Guillain-Barré syndrome, influenzalike illnesses, and influenza vaccination
during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol
174: 326–335.
17. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, et al. (2011)
Neurological and autoimmune disorders after vaccination against pandemic
influenza A (H1N1) with a monovalent adjuvanted vaccine: population based
cohort study in Stockholm, Sweden. BMJ 343: d5956.
18. Andrews N, Stowe J, Al-Shahi Salman R, Miller E (2011) Guillain-Barré
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Background and purpose: We have previously shown that patients with multi-
ple sclerosis receiving immunomodulatory treatment have reduced seroprotec-
tion rates after influenza immunization. The aim of this study was to further
investigate the influence of immunomodulatory therapies on the antibody
response and seroprotection rates in patients immunized with seasonal influ-
enza vaccine in 2012/2013 compared with healthy controls.
Methods: Ninety patients receiving fingolimod, glatiramer acetate, interferon
beta-1a/1b, natalizumab or no therapy were compared with 62 healthy con-
trols. All subjects received the inactivated split virus vaccine in 2012 and
serum samples were collected pre-vaccination and 3, 6 and 12 months post-
vaccination. The vaccine responses were evaluated by the hemagglutination
inhibition assay and adjusted for age and gender.
Results: No significant differences in rates of protection against H1N1 for
interferon beta-1a/1b and glatiramer acetate were observed as compared with
controls at 3, 6 and 12 months. Fingolimod provided reduced protection at all
time points post-vaccination, whereas natalizumab displayed reduced protec-
tion at 3 and 6 months. Patients without immunomodulation did not display
protection rates that were significantly different from the controls at 3 and
12 months.
Conclusion: These findings suggest that patients with multiple sclerosis receiv-
ing fingolimod or natalizumab should be considered for a second dose of the
vaccine in cases of insufficient protection. Our results further indicate that new
immunomodulatory treatment regimens should be systematically evaluated for
their influence on influenza-specific vaccine responses.
Introduction
Influenza is a highly contagious acute respiratory
virus causing annual global epidemics resulting in sub-
stantial morbidity and mortality particularly in high-
risk patients with underlying disease. Vaccination is
the main method of prophylaxis, and annual vaccina-
tion is recommended for all high-risk patients. In
addition to the risk of morbidity and mortality due to
the influenza infection itself, it also increases the risk
for worsening of multiple sclerosis (MS) [1]. Thus,
there is a strong rationale for influenza immunization
in patients with MS [2–4]. It has been shown that vac-
cines do not cause MS, MS relapse or central nervous
system demyelination [5], and that inactivated influ-
enza vaccines are considered safe in patients with MS
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[6,7]. Immunomodulatory and immunosuppressive
treatments for MS are associated with an increased
risk of infection, making treatment of this condition
challenging in daily clinical practice [8]. Few data exist
on how long one should wait after vaccination before
starting a therapy, although it is worth considering
measuring the effect of immunization using antibody
levels [7].
We have previously shown that the differential
immunization effect was dependent on subtype of
immunomodulation in patients with MS, where only
interferon beta-1a/1b did not influence the protection
rate compared with other therapies [9]. In this follow-
up study, we analysed the immunogenicity of influ-
enza vaccination in patients with MS during treatment
with five different immunomodulatory therapies after
seasonal influenza vaccination in 2012/2013, with
baseline sampling and follow-up after 3, 6 and
12 months in both the study population and controls.
Materials and methods
Study design
This was a prospective study with follow-up of
patients and controls with measurement of the vac-
cine-specific antibody responses to the influenza A
H1N1 and H3N2 2012/2013 influenza vaccine viruses
at visit 1 (day 0), visit 2 (3 months), visit 3 (6 months)
and visit 4 (12 months).
Patients and controls
Ninety patients with MS (mainly relapsing-remitting)
at the Department of Neurology, Haukeland Univer-
sity Hospital, Bergen, Norway were included from
December 2012 to February 2013. The patients
received one of the following immunomodulatory
therapies: fingolimod (n = 15), glatiramer acetate
(n = 23), interferon beta-1a/1b (n = 25), natalizumab
(n = 12) or none. The controls (n = 62) were health-
care workers at the Haukeland University Hospital in
Bergen without immunotherapy or neurological dis-
ease recruited during the same period. Age and gender
were recorded for all participants (Table S1). All
patients and controls provided written informed con-
sent. The Regional Ethics Committee/REK Vest trial
numbers were 2010/745 and 2009/1224. All data were
anonymized.
Vaccination
All participants received the trivalent inactivated unadju-
vanted split influenza virus vaccine that contained
A/California/07/2009 (H1N1)pdm09, A/Victoria/361/
2011 (H3N2) and B/Wisconsin/1/2010 (Vaxigrip, Sanofi
Pasteur MSD, Lyon, France or Fluarix, GSK, Rixensart,
Belgium).
Blood sampling and hemagglutination inhibition assay
Serum samples for analyses of influenza vaccine
responses were drawn pre-vaccination (day 0) and 3, 6
and 12 months post-vaccination. Samples were allo-
cated a laboratory number and stored at 80°C until
used in the blinded analyses. The numbers of missing
blood samples varied throughout the study period,
and were highest at 12 months (Tables 1 and 2). Sera
were treated with receptor-destroying enzyme (one
volume of serum was diluted with four volumes of
receptor-destroying enzyme) and tested by the hemag-
glutination inhibition (HI) assay as described in Mad-
hun et al. [10]. In brief, a twofold dilution series of
sera was prepared in phosphate-buffered saline (start-
ing dilution 1/10) and incubated with 8 hemagglutinin
units of whole inactivated H1N1 (A/California/07/
2009) or H3N2 (A/Victoria/361/2011) virus (Interna-
tional Reagent Resource, Manassas, VA, USA) for
Table 1 Post-vaccination comparison of H1N1-specific hemagglutination inhibition (HI) responses after seasonal influenza vaccination in
Hordaland, Norway (2012/2013) in 90 patients with multiple sclerosis (MS) and 62 controlsa
Group
Day 0 3 months 6 months 12 months
n GMT % protectedb n GMT % protected n GMT % protected n GMT % protected
Controls 53 154.8 90.6 56 206.2 94.6 50 180.4 94.0 54 82.3 70.4
MS 90 36.7 45.6 87 117.0 85.1 76 93.6 76.3 71 63.7 63.4
Fingolimod 15 42.2 40.0 14 87.6 71.4 12 93.6 58.3 9 33.3 22.2
Glatiramer acetate 23 43.2 56.5 23 112.3 91.3 22 112.4 86.4 22 84.8 77.3
Interferon beta-1a/1b 25 28.1 36.0 25 164.2 88.0 19 87.6 84.2 19 89.8 79.0
Natalizumab 12 53.9 50.0 11 115.4 72.7 8 123.9 75.0 9 52.7 55.6
None 15 28.7 46.7 14 92.1 92.9 15 66.9 66.7 12 41.1 50.0
Total 143 143 126 125
GMT, geometric mean titre. aSome patients and controls are missing at different time points. bProtection is defined as an HI titre ≥ 40.
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1 h; 0.7% turkey erythrocytes were added for 30 min
before reading. Positive control ferret sera (Interna-
tional Reagent Resource) were included in all assays.
All sera were tested in duplicate and the geometric
mean titer (GMT) was calculated. The serum HI titer
was expressed as the reciprocal of the highest dilution
at which 50% hemagglutination was inhibited, and
the titers <10 were assigned a value of 5 for calcula-
tion purposes. This assay is commonly used to mea-
sure influenza-specific antibody responses after
vaccination. An HI titer ≥40 is established as a surro-
gate correlate of protection and is used in this study
to define protection. The immunogenicity of the influ-
enza B strain was not tested, due to lack of sensitivity
in the HI test.
Statistical methods
Descriptive statistics are reported using the mean, geo-
metric mean, SD, frequency counts and percentage.
Associations between categorical variables were tested
using Pearson’s chi-square test.
Mixed linear regression was performed to analyse the
dependency of H1N1 and H3N2, respectively, related
to therapy (fingolimod, glatiramer acetate, interferon
beta-1a/1b, natalizumab and no treatment compared
with controls) adjusted for age and gender assuming an
autoregressive correlation of the first order to account
for correlation between repeated measurements in each
subject. The residuals were examined to check for con-
sistency with the normality assumption (Figs S1 and
S2), and log transformation of H1N1 and H3N2 was
chosen for the analysis. All models were inspected for
interactions between time and medication group.
The rate of protection, defined as H1N1 ≥ 40 and
H3N2 ≥ 40, respectively, was analysed with respect to
the same variables using logistic regression and the
generalized estimating equations methodology. Results
are reported using the odds ratio and 95% confidence
interval. SPSS version 23.0 (Armonk, NY, USA) was
used for all statistical analyses. The significance level
was set at 0.05 for all tests.
Results
Demographic variables
Clinical and demographic variables at baseline are
shown in Table S1. The MS group was on average
about 4 years older and included fewer women than
the control group.
H1N1-specific antibody responses to seasonal
influenza vaccination
The post-vaccination comparison of the HI response in
patients with MS and controls is shown in Table 1. Results
from the mixed linear regression are given in Table 3 and
results from logistic regression are shown in Table 4.
Age had a negative effect on ln(H1N1) HI titers in
the mixed linear model (P = 0.003), as shown by an
increasing age of 10 years giving an approximate 20%
decrease in H1N1-specific antibody titers. In the
mixed linear regression, gender did not influence the
outcome (P = 0.337).
Influence of immunomodulation on the H1N1-specific
vaccination response with time
Figure 1 shows the mean H1N1 GMT HI titers for
each medication at all visits unadjusted for age and
gender on a log2 scale.
The mixed linear regression of ln(H1N1) HI titers
showed a significant interaction between time and med-
ication after adjustment for age and gender
(P < 0.001). Antibody titers increased significantly at
all study visits after vaccination compared with pre-vac-
cination titers in patients with MS treated with
Table 2 Post-vaccination comparison of H3N2 hemagglutination inhibition (HI) responses after seasonal influenza vaccination in Hordaland,
Norway (2012/2013) in 90 patients with multiple sclerosis (MS) and 62 controlsa
Group
Day 0 3 months 6 months 12 months
n GMT % protectedb n GMT % protected n GMT % protected n GMT % protected
Controls 53 44.7 56.6 56 89.8 69.6 50 52.0 58.0 54 50.4 57.4
MS 90 7.7 3.3 86 30.4 33.7 76 23.4 27.6 70 17.0 21.4
Fingolimod 15 7.3 0.0 14 16.8 21.4 12 16.3 8.3 8 12.7 0.0
Glatiramer acetate 23 9.1 8.7 23 26.8 26.1 22 19.9 27.3 22 18.7 27.3
Interferon beta-1a/1b 25 7.3 0.0 25 46.9 44.0 19 38.8 47.4 19 24.7 36.8
Natalizumab 12 7.3 8.3 10 25.8 30.0 9 15.3 11.1 9 10.1 0.0
None 15 7.1 0.0 14 35.0 42.9 14 27.3 28.6 12 14.2 16.7
Total 143 7.4 142 126 124
GMT, geometric mean titre. aSome patients and controls are missing at different time points. bProtection is defined as an HI titre ≥ 40.
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interferon beta-1a/1b and glatiramer acetate. Fin-
golimod and natalizumab provided reduced protection
at all time points post-vaccination. The group without
medication also had significant increase in antibody
titers at 3 and 12 months post-vaccination. The con-
trols showed significant changes in HI titers with time
(P < 0.001), with significantly higher titers at 3 months
post-vaccination, which decreased to be significantly
lower than pre-vaccination titers at 12 months post-
vaccination. The absence of immunotherapy provided a
significant increase in GMT at 3 and 12 months, but
not at 6 months.
An HI titer ≥40 is considered protective. For analy-
ses of protection (H1N1 ≥ 40) using the logistic
regression model, adjustment for age and sex gave
only marginal changes. The logistic regression of
H1N1-specific titers showed a significant interaction
between time and medication (P = 0.001). There were
significant differences between the therapy groups
including the controls (P = 0.007) pre-vaccination.
The pre-vaccination rates of protection were signifi-
cantly lower in all medication groups compared with
the controls. At 3 months, which is the time of the
peak antibody response, interferon, glatiramer acetate
Table 3 Results from the mixed linear regression analysis of ln(H1N1) and ln(H3N2) hemagglutination inhibition titers after seasonal influenza
vaccination in Hordaland, Norway (2012/2013) in 90 patients with multiple sclerosis and 62 controls
ln(H1N1) ln(H3N2)
Variable b 95% CI P b 95% CI P
Intercept 6.29 5.41 to 7.17 <0.001 3.39 2.54 to 4.25 <0.001
Age (years) 0.02 0.04 to 0.01 0.003 0.00 0.02 to 0.02 0.974
Female 0.20 0.60 to 0.21 0.337 0.11 0.28 to 0.49 0.592
Medication 0.014 <0.001
Interferon beta-1a/1b 1.69 2.30 to 1.08 1.01 1.52 to 0.49
Glatiramer acetate 1.03 1.67 to 0.40 1.22 1.75 to 0.68
Natalizumab 1.19 2.00 to 0.38 1.55 2.25 to 0.86
Fingolimod 1.35 2.09 to 0.62 1.49 2.13 to 0.86
No medication 1.39 2.17 to 0.60 1.22 1.90 to 0.54
Control 0.00 Reference 0.00 Reference
Time (months) <0.001 <0.001
0 0.00 Reference 0.00 Reference
3 0.36 0.14 to 0.58 1.12 0.91 to 1.33
6 0.27 0.03 to 0.57 0.76 0.50 to 1.03
12 0.54 0.88 to 0.20 0.59 0.29 to 0.89
Time 9 medication <0.001 0.234a
0 9 control 0.00 Reference Not included
3 9 control 0.00 Reference
6 9 control 0.00 Reference
12 9 control 0.00 Reference
0 9 interferon beta-1a/1b 0.00 Reference
3 9 interferon beta-1a/1b 1.41 1.02 to 1.80
6 9 interferon beta-1a/1b 1.09 0.55 to 1.64
12 9 interferon beta-1a/1b 1.81 1.18 to 2.44
0 9 glatiramer acetate 0.00 Reference
3 9 glatiramer acetate 0.60 0.19 to 1.00
6 9 glatiramer acetate 0.68 0.14 to 1.22
12 9 glatiramer acetate 1.21 0.58 to 1.83
0 9 natalizumab 0.00 Reference
3 9 natalizumab 0.41 0.11 to 0.93
6 9 natalizumab 0.33 0.41 to 1.06
12 9 natalizumab 0.66 0.19 to 1.50
0 9 fingolimod 0.00 Reference
3 9 fingolimod 0.38 0.09 to 0.86
6 9 fingolimod 0.39 0.26 to 1.04
12 9 fingolimod 0.52 0.29 to 1.32
0 9 no medication 0.00 Reference
3 9 no medication 0.94 0.47 to 1.42
6 9 no medication 0.58 0.05 to 1.20
12 9 no medication 1.16 0.41 to 1.91
b, estimated regression coefficient; CI, confidence interval. aFrom model with interaction term included.
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and the group without treatment showed no signifi-
cant differences in protection rates as compared with
the controls, whereas protection rates for fingolimod
and natalizumab were significantly lower. Also, at
6 months, interferon and glatiramer acetate showed
protection rates that were not significantly different
from the controls, whereas protection rates for fin-
golimod, natalizumab and the group without treat-
ment were significantly lower. At 12 months,
interferon, glatiramer acetate, natalizumab and those
without treatment showed no significant differences in
protection rates as compared with the controls,
whereas protection rates in patients on fingolimod
were significantly lower.
H3N2-specific antibody responses to seasonal
influenza vaccination
The post-vaccination comparison of the HI response in
patients with MS and controls is shown in Table 2.
Results from the mixed linear regression are given in
Table 3 and the logistic regression is shown in Table 4.
Table 4 Results from logistic regression analysis of protection rates against influenza H1N1and H3N2 viruses after seasonal influenza
vaccination in Hordaland, Norway (2012/2013) in 90 patients with multiple sclerosis and 62 controls
H1N1 ≥ 40 H3N2 ≥ 40
Variablea ORb 95% CI Pc OR 95% CI P
Intercept 8.71 3.69 to 20.56 <0.001 0.86 0.53 to 1.42 <0.001
Medication 0.007 <0.001
Interferon beta-1a/1b 0.23 0.11 to 0.50
Glatiramer acetate 0.14 0.05 to 0.39
Natalizumab 0.07 0.02 to 0.23
Fingolimod 0.06 0.02 to 0.20
No medication 0.16 0.06 to 0.41
Control 1.00 Reference
Time (months) <0.001 <0.001
0 1.00 Reference 1.00 Reference
3 2.36 0.88 to 6.33 3.88 2.54 to 5.91
6 2.28 0.82 to 6.32 2.45 1.53 to 3.93
12 0.29 0.12 to 0.67 2.03 1.31 to 3.14
Time 9 medication 0.001 Not included n.s.d
0 9 control 1.00 Reference
0 9 interferon beta-1a/1b 0.06 0.02 to 0.21
0 9 glatiramer acetate 0.15 0.05 to 0.49
0 9 natalizumab 0.11 0.03 to 0.48
0 9 fingolimod 0.08 0.02 to 0.29
0 9 no medication 0.10 0.03 to 0.38
3 9 control 1.00 Reference
3 9 interferon beta-1a/1b 0.36 0.06 to 2.02
3 9 glatiramer acetate 0.51 0.08 to 3.46
3 9 natalizumab 0.13 0.02 to 0.74
3 9 fingolimod 0.12 0.02 to 0.65
3 9 no medication 0.79 0.05 to 12.77
6 9 control 1.00 Reference
6 9 interferon beta-1a/1b 0.35 0.06 to 2.16
6 9 glatiramer acetate 0.33 0.06 to 1.91
6 9 natalizumab 0.09 0.01 to 0.56
6 9 fingolimod 0.06 0.01 to 0.33
6 9 no medication 0.10 0.02 to 0.53
12 9 control 1.00 Reference
12 9 interferon beta-1a/1b 1.74 0.48 to 6.31
12 9 glatiramer acetate 1.36 0.43 to 4.31
12 9 natalizumab 0.62 0.16 to 2.43
12 9 fingolimod 0.19 0.05 to 0.69
12 9 no medication 0.50 0.14 to 1.73
CI, confidence interval; n.s., not significant; OR, odds ratio. P value from likelihood ratio test. aFor both H1N1 and H3N2 adjusting for age
(n.s.) and sex (n.s.) gave marginal changes. bFrom model without main effect from medication, to obtain time-specific estimates for each medi-
cation vs. controls. cFrom model with main effects and interaction. dThe model with interaction between time and medication could not be esti-
mated due to numerical problems. However, analysis with four groups (interferon, non-interferon, no medication and controls) showed no
significant interaction.
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Neither age nor gender affected the rates of protec-
tion (P = 0.974 and P = 0.592, respectively).
Influence of immunomodulation on the H3N2-specific
vaccination response with time
Figure 2 shows the mean H3N2 GMT HI titers for
each therapy at all visits unadjusted for age and gen-
der on a log2 scale.
The mixed linear regression of H3N2 showed signif-
icant differences according to therapy (P < 0.001) and
time (P < 0.001) but not between therapies and time
(P = 0.234).
In the logistic regression model of protection, the
interaction between time and medication was not sig-
nificant but all medication groups had significantly
increased protection rates post-vaccination at all time
points compared with pre-vaccination rates (P < 0.001).
Nevertheless, patients with MS were significantly less
likely to be protected when compared with the controls
at all time points (P < 0.001).
Discussion
We have previously shown that patients with MS
receiving immunomodulatory treatment except for
interferon beta-1a/1b had reduced antibody responses
and protection rates after influenza immunization.
Samples were drawn at an average of 10 months after
the pandemic swine influenza vaccination in 2009 and
6 months after the seasonal influenza vaccination in
2010. In the present study, we have extended our
work to evaluate the influence of different
immunomodulatory therapies in patients with MS
immunized with seasonal influenza vaccine in 2012/
2013 on the time course of the antibody response and
protection rates compared with healthy controls.
Compared with the controls, our data show signifi-
cantly reduced protection rates in patients receiving
fingolimod and natalizumab, whereas such reduction
could not be demonstrated in patients receiving inter-
feron beta-1a/1b, glatiramer acetate or in untreated
patients.
One previous study has reported no influence of fin-
golimod on the protective response after the influenza
vaccination periods in the 2008/2009 and 2009/2010
seasons by enzyme-linked immunosorbent assay anal-
yses in 14 patients and sampling times 0, 7, 14 and
28 days post-vaccination [11]. Another study reported
reduced response rates after 3 and 6 weeks with the
HI method in 95 patients during the 2010/2011 season
[12]. Our results based on the HI method are






















Figure 1 Geometric mean hemagglutination inhibition serum
antibody titers to H1N1 plotted on log2 scale according to time
since vaccination and medication including multiple sclerosis
(MS) vs. control group. Blue, controls; green, MS; brown, fin-
golimod; purple, glatiramer acetate; yellow, interferon beta-1a/
1b; red, natalizumab; pale blue, none.






















Figure 2 Geometric mean hemagglutination inhibition serum
antibody titers to H3N2 plotted on log2 scale according to time
since vaccination and medication including multiple sclerosis
(MS) vs. control group. Blue, controls; green, MS; brown, fin-
golimod; purple, glatiramer acetate; yellow, interferon beta-1a/
1b; red, natalizumab; pale blue, none.
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consistent with reduced protection at all time points
post-vaccination, similar to the latter study. Fin-
golimod is a sphingosine 1-phosphate receptor func-
tional antagonist that blocks egress of CCR7+ CD4+
naive and central memory T cells from the lymph
nodes. The effect on the immune system is lymphocyte
redistribution [8], which might confer a reduced
immune response and thus reduced protection after
vaccination.
For glatiramer acetate, few data exist except from
our previous explorative study where we found possi-
ble reduced long-term protection [9]. In the present
study, we found protection rates for glatiramer acetate
that were similar to interferon beta-1a/1b, which
might be due to more patients receiving this drug in
the present study as compared with our pilot study.
Rates of protection after influenza immunization in
patients receiving interferon beta have been reported
to be unchanged in several studies [3,9,13,14], as con-
firmed in the present study. This applies for all post-
vaccination time points.
We reported lower protection rates during natal-
izumab therapy in our previous study using the HI
method in 17 patients vaccinated during 2009/2010
sampled at 10 months and in 8 patients vaccinated in
2010/2011 sampled at 6 months [9]. Others have, how-
ever, found unchanged protection if vaccinated with a
strongly immunogenic protein but not an influenza
antigen in 30 patients sampled at 28 and 56 days
post-vaccination and measured by enzyme-linked
immunosorbent assay [15]. Another study reported
reduced vaccine response to influenza A but not to
influenza B compared with controls, which is compati-
ble with our results. This study included 17 patients in
the 2010/2011 season sampled at 4, 8 and 12 weeks
post-vaccination measured by an in-house-developed
enzyme-linked immunosorbent assay [16]. In the pre-
sent study we found significantly reduced protection
rates at 3 and 6 months compared with the controls,
but at 12 months the reduced protection rates were
more similar to and not significantly different from
that of the controls. We did not analyse the response
to influenza B, due to lack of sensitivity in the HI
method. Natalizumab is a humanized monoclonal
anti-a4-integrin antibody that prevents T and NK
cells from crossing blood vessels to reach affected
organs and also induces lymphocyte apoptosis. The
effect on the immune system is diminished immune
surveillance in the central nervous system [8]. The tri-
als that led to approval of the drug for relapsing-
remitting MS (AFFIRM and SENTINEL) showed an
overall elevation in the incidence of infections, includ-
ing influenza. This might confer a reduced response
and thus reduced protection after vaccination.
The controls had significantly higher pre-vaccina-
tion H1N1 protection rates, but this was probably
attributable to the receipt of the same vaccine yearly
for the last 4 years. Additionally, the antigenicity of
the circulating H1N1 virus has been unchanged since
the pandemic of 2009. Further, the pandemic influ-
enza vaccine in 2009 contained the AS03 adjuvant
that potentiated the immunogenicity of the vaccine to
provide increased HI antibody titers and additional
protection with a longer lasting response for up to
3 years. Thus, any differences between MS and con-
trols in this study are probably underestimated.
All rates of protection against H3N2 were lower pre-
and post-vaccination as previously reported, but this
was also the case for the controls. In particular, the
H3N2 pre-vaccination titers in all patients indicated
that they had either not been previously exposed to the
virus or alternatively had high antibody waning rates
leading to lower protective titers. Additionally, the
H3N2 virus antigenicity has changed frequently since
1968. The patient group with interferon beta-1a/1b
showed the highest increase, but no conclusion could be
reached for any of the medications according to time.
Vaccines play an important role in the prevention
of treatment-associated infections, and are encouraged
in MS and in particular before the initiation of disease-
modifying therapies whenever possible [17], although
no large data series or evidence-based recommendation
exists for optimal timing of seasonal influenza vaccina-
tion during long-term immunomodulation.
Conclusion
Patients with MS who received fingolimod or natal-
izumab, but not interferon beta-1a/1b or glatiramer
acetate, had reduced protection rates after influenza
vaccination. These findings suggest that patients with
MS receiving fingolimod or natalizumab should be
considered for a second dose of the vaccine in cases
of insufficient protection. Our results further indicate
that new immunomodulatory treatment regimens
should be systematically evaluated for influence on
influenza-specific vaccine responses.
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